ConMed

US · CNMD #3018 by market cap Listed 1970

44.23 -0.25 -0.56%

Live - 5344 symbols - heartbeat 487s ago · 2026-10-08 07:01

Pre-market 43.92 -0.69%

After-hours 44.23 0.00%

Overnight 44.24 +0.02%

Market cap: 1.32B
P/E (TTM): 23.91
P/B: 1.27
EPS: 1.51
Div yield: 0.45%
52W pos: 58%

Reader sentiment Are you bullish or bearish on CNMD?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Fair

Altman Z-Score is 1.89, in the 1.8-3.0 "grey zone".
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +5.18% YoY

Margins

Gross margin: 54.59%
Operating margin: 7.46%
Net margin: 3.42%

Key ratios & quality

Enterprise value: 2.12B
Altman Z-Score: 1.89

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	859.63M	955.10M	862.46M	1.01B	1.05B	1.24B	1.31B	1.37B
Gross profit	469.11M	524.72M	460.30M	568.04M	571.25M	676.25M	733.03M	750.48M
Selling & admin expenses	355.62M	400.14M	373.82M	414.75M	454.04M	503.04M	478.28M	591.97M
Research & development	42.19M	45.46M	40.47M	43.57M	47.15M	52.60M	54.43M	55.88M
Operating profit	71.31M	79.11M	46.01M	109.72M	70.05M	120.60M	200.33M	102.62M
Pretax profit	50.65M	31.23M	1.60M	73.11M	-70.86M	80.83M	163.03M	71.12M
Tax	9.80M	2.61M	-7.91M	10.56M	9.72M	16.37M	30.61M	24.06M
Net profit	40.85M	28.62M	9.52M	62.54M	-80.58M	64.46M	132.42M	47.06M
Basic EPS	1	1	0	2	-3	2	4	2
Diluted EPS	1.41	0.97	0.32	1.94	-2.68	2.04	4.25	1.51

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	321.26M	342.35M	337.93M	373.20M	317.05M	343.49M
Gross profit	177.75M	188.32M	166.12M	218.29M	183.45M	197.46M
Selling & admin expenses	148.85M	136.02M	140.34M	166.76M	141.70M	145.55M
Research & development	12.95M	14.14M	13.90M	14.90M	16.33M	15.50M
Operating profit	15.96M	38.16M	11.88M	36.62M	25.42M	36.41M
Pretax profit	7.67M	29.92M	4.27M	29.25M	18.36M	31.35M
Tax	1.64M	8.50M	1.41M	12.51M	4.53M	8.28M
Net profit	6.04M	21.42M	2.86M	16.74M	13.83M	23.07M
Basic EPS	0	1	0	1	0	1
Diluted EPS	0.19	0.69	0.09	0.54	0.45	0.77

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	374.35M	397.36M	416.65M	460.12M	581.23M	615.65M	640.01M	672.86M
Cash & ST investments	17.51M	25.86M	27.36M	20.85M	28.94M	24.30M	24.46M	40.82M
Inventory	154.60M	164.62M	194.87M	231.64M	332.32M	318.32M	346.72M	355.54M
Total assets	1.37B	1.78B	1.75B	1.77B	2.30B	2.30B	2.31B	2.33B
Total current liabilities	160.94M	188.09M	190.20M	196.65M	296.55M	310.73M	278.13M	315.04M
Short-term debt	18.34M	20.86M	18.42M	12.25M	69.75M	708.00K	715.00K	712.00K
Long-term debt	438.56M	754.72M	735.22M	672.41M	985.08M	973.14M	905.07M	834.23M
Total liabilities	706,868,000.00	1,064,628,000.00	1,042,635,000.00	980,582,000.00	1,552,047,000.00	1,465,799,000.00	1,343,566,000.00	1,292,652,000.00
Total equity	662.27M	710.47M	709.04M	785.44M	745.55M	834.22M	962.68M	1.03B
Retained earnings	464.85M	470.84M	457.42M	496.61M	412.63M	452.53M	560.28M	588.77M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	639.00M	657.78M	662.16M	672.86M	670.59M	675.67M
Cash & ST investments	35.49M	33.94M	38.93M	40.82M	35.03M	37.33M
Inventory	354.68M	362.25M	364.36M	355.54M	366.11M	360.18M
Total assets	2.30B	2.33B	2.32B	2.33B	2.31B	2.30B
Total current liabilities	283.15M	294.84M	314.70M	315.04M	292.72M	455.40M
Short-term debt	714.00K	714.00K	746.00K	712.00K	711.00K	177.20M
Long-term debt	891.44M	881.11M	853.01M	834.23M	860.16M	657.05M
Total liabilities	1,320,047,000.00	1,325,588,000.00	1,314,225,000.00	1,292,652,000.00	1,297,269,000.00	1,258,916,000.00
Total equity	977.64M	1.00B	1.01B	1.03B	1.02B	1.04B
Retained earnings	560.13M	575.36M	572.03M	588.77M	602.59M	625.67M

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	74.70M	95.13M	64.53M	111.77M	33.37M	125.35M	166.97M	170.69M
Depreciation & amortization	60.76M	72.32M	72.63M	70.74M	69.52M	71.87M	71.86M	74.28M
Free cash flow	58.19M	75.07M	51.52M	96.90M	11.58M	106.32M	153.88M	150.88M
Dividends paid	-22.44M	-22.60M	-22.82M	-23.26M	-23.96M	-24.50M	-24.65M	-24.75M
Stock buybacks / issuance	--	--	--	--	--	--	--	--
Ending cash balance	17.51M	25.86M	27.36M	20.85M	28.94M	24.30M	24.46M	40.82M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	41.53M	29.13M	53.69M	46.34M	13.47M	37.10M
Depreciation & amortization	18.25M	18.57M	18.61M	18.85M	18.84M	19.05M
Free cash flow	37.76M	23.41M	48.50M	41.22M	10.58M	34.16M
Dividends paid	-6.18M	-6.19M	-6.19M	-6.19M	0	0
Stock buybacks / issuance	0	0	--	--	-37.02M	-6.20M
Ending cash balance	35.49M	33.94M	38.93M	40.82M	35.03M	37.33M

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	6.32	4.17	1.34	8.37	-10.53	8.16	14.74	4.72
ROA %	3.00	1.82	0.54	3.56	-3.97	2.80	5.75	2.03
ROIC %	5.14	5.22	2.81	6.29	-3.62	5.33	8.85	3.62
5-year avg ROE %	5.73	5.48	4.70	5.87	1.93	2.30	4.42	5.09
EBIT margin %	8.29	7.74	5.29	10.74	-4.01	9.69	15.33	7.43
FCF / sales %	6.77	7.86	5.97	9.59	1.11	8.54	11.77	10.98
Current ratio	2.33	2.11	2.19	2.34	1.96	1.98	2.30	2.14
Quick ratio	1.24	1.14	1.08	1.04	0.74	0.86	0.94	0.92
Debt / assets	33.37	44.68	43.02	38.77	45.91	42.34	39.28	35.90
LT debt / equity	66.22	108.70	103.69	85.61	132.13	116.65	94.02	80.75
Interest coverage	3.45	1.73	1.04	3.06	-1.45	3.03	5.37	3.29
Revenue CAGR (3Y) %	6.13	7.75	2.69	5.54	3.06	13.01	8.95	9.56
Net income CAGR (3Y) %	10.24	24.97	-44.44	15.25	--	89.20	28.41	--
FCF CAGR (3Y) %	17.46	44.02	-0.77	18.53	-46.37	27.32	16.67	135.31

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	12.96	11.69	6.60	4.72	5.50	5.53
ROA %	5.16	4.78	2.76	2.03	2.38	2.44
ROIC %	7.98	7.37	4.74	3.62	3.99	4.09
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	13.77	12.96	8.76	7.43	8.15	8.25
FCF / sales %	12.50	11.18	11.05	10.98	9.03	9.80
Current ratio	2.26	2.23	2.10	2.14	2.29	1.48
Quick ratio	0.91	0.91	0.84	0.92	0.90	0.61
Debt / assets	38.83	37.87	36.76	35.90	37.19	36.27
LT debt / equity	91.18	87.86	84.60	80.75	84.52	63.09
Interest coverage	5.04	5.02	3.63	3.29	3.74	3.78
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail

General surgery is the largest reported line at 55.66% of revenue, across 2 reported segments.
Orthopedic surgery follows at 44.34%, so the top line still matters most but isn’t the whole story.

Revenue breakdown most recent period

Business

General surgery55.66%

Orthopedic surgery44.34%

Quote time 2026-10-08 07:01:20 · For reference only, not investment advice and not tailored to your situation.